The aerosol delivery devices market has seen considerable growth due to a variety of factors.
• The aerosol delivery devices market will grow from $47.6 billion in 2024 to $51.63 billion in 2025 at a CAGR of 8.5%.
Growth drivers include the rising prevalence of respiratory diseases, regulatory approvals, greater adoption of portable devices, increasing healthcare spending, awareness campaigns on respiratory health, and government initiatives.
The aerosol delivery devices market is expected to maintain its strong growth trajectory in upcoming years.
• The aerosol delivery devices market is expected to grow to $70.79 billion by 2029, at a CAGR of 8.2%.
The growth is driven by expanding use in chronic disease management, increasing demand for personalized medicine, rising air pollution, and an aging population. Major trends include advancements in drug delivery, generic alternatives, biologics and specialty drugs, and nanotechnology for aerosol delivery.
The growing prevalence of respiratory diseases is expected to drive the growth of the aerosol delivery device market. Respiratory conditions, such as asthma and other lung diseases, are on the rise due to factors like air pollution and smoking. Aerosol delivery devices are crucial for effectively delivering medications to the lungs, improving patient compliance and therapeutic outcomes. For example, in May 2024, the National Center for Health Statistics reported a rise in the prevalence of asthma among U.S. adults from 8% in 2021 to 8.7% in 2022. The increasing prevalence of respiratory diseases will drive the demand for aerosol delivery devices.
The aerosol delivery devices market covered in this report is segmented –
1) By Product: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers
2) By Application: Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, Non Respiratory Diseases
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, E Commerce
Subsegments:
1) By Dry Powder Inhalers (DPIs): Single-Dose DPIs, Multi-Dose DPIs
2) By Metered Dose Inhalers (MDIs): Conventional MDIs, MDIs With Spacer/Chamber
3) By Nebulizers: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers
Companies in the aerosol delivery device market are focusing on enhancing medication adherence with innovative products like intelligent inhaler dose trackers. For example, in June 2024, Aseptika Ltd., a UK-based MedTech company, introduced the PUFFClicker3 Universal Inhaler. This smart inhaler dose counter attaches to various inhalers, monitors doses in real-time, and syncs with health apps via Bluetooth, helping patients adhere to their medication schedules and providing real-time data to healthcare providers.
Major companies operating in the aerosol delivery devices market are:
• Pfizer Inc
• Merck & Co Inc
• AstraZeneca plc
• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc (GSK)
• 3M Company
• Becton Dickinson and Company
• Koninklijke Philips NV
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd
• Sandoz International GmbH
• Draegerwerk AG & Co KGaA
• Shionogi & Co Ltd
• Hikma Pharmaceuticals PLC
• Chiesi Farmaceutici SpA
• Vectura Group plc
• Fresenius Kabi AG
• Metall Zug AG
• Sunovion Pharmaceuticals Inc.
• Omron Healthcare Inc.
• PARI GmbH
• Aerogen Inc
• Clement Clarke International Ltd
• Iconovo AB
North America was the largest region in the aerosol delivery devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aerosol delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.